SY-5609
| | • | | Initiate Phase 1 trial ofSY-5609 in first quarter of 2020 in patients with breast, colorectal, lung and ovarian cancers, as well as in patients with solid tumors of any histology harboring Rb pathway alterations. |
| | • | | Report initial safety, tolerability, pharmacokinetic and pharmacodynamic data in fourth quarter of 2020 from dose escalation portion of Phase 1 trial. |
| | • | | Report additional dose escalation data, including clinical activity data, inmid-2021. |
Preclinical Pipeline
| | • | | Syros expects to nominate its next development candidate by the end of 2021. |
Syros also announced today that the Company’s second monogenic disease program is in myotonic dystrophy type 1.
Financial Guidance
Based on its current operating plans, Syros expects that its existing cash, cash equivalents and marketable securities are sufficient to fund its anticipated operating expenses and capital expenditure requirements into the fourth quarter of 2021 through key clinical milestones for bothSY-1425 andSY-5609.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, includingSY-1425, afirst-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, andSY-5609, a highly selective and potent oral CDK7 inhibitor expected to enter a Phase 1 trial in cancer in the first quarter of 2020. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the timing for reporting and the quality of data from the ongoing clinical evaluating SY-1425 in combination with azacitidine in AML patients, the initiation of a Phase 1 clinical trial ofSY-5609 in the first quarter and the timing for reporting data from this trial, the ability to bring an oral medicine to market that provides a functional cure for sickle cell disease or beta thalassemia patients, the advancement of the Company’s preclinical and discovery programs, the timing for nomination of the Company’s next development candidate, and the sufficiency of the Company’s capital resources to fund operating expense and capital expenditure requirements into the fourth quarter of 2021 through key clinical milestones. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’
